

Ophthalmic implants - Ophthalmic viscosurgical devices (ISO 15798:2022)

This document is a preview generated by EVS

EESTI STANDARDI EESSÕNA

NATIONAL FOREWORD

See Eesti standard EVS-EN ISO 15798:2022 sisaldab Euroopa standardi EN ISO 15798:2022 ingliskeelset teksti.	This Estonian standard EVS-EN ISO 15798:2022 consists of the English text of the European standard EN ISO 15798:2022.
Standard on jõustunud sellekohase teate avaldamisega EVS Teatajas	This standard has been endorsed with a notification published in the official bulletin of the Estonian Centre for Standardisation and Accreditation.
Euroopa standardimisorganisatsioonid on teinud Euroopa standardi rahvuslikele liikmetele kättesaadavaks 09.02.2022.	Date of Availability of the European standard is 09.02.2022.
Standard on kättesaadav Eesti Standardimis- ja Akrediteerimiskeskusest.	The standard is available from the Estonian Centre for Standardisation and Accreditation.

Tagasisidet standardi sisu kohta on võimalik edastada, kasutades EVS-i veebilehel asuvat tagasiside vormi või saates e-kirja meiliaadressile standardiosakond@evs.ee.

ICS 11.040.70

Standardite reprodutseerimise ja levitamise õigus kuulub Eesti Standardimis- ja Akrediteerimiskeskusele

Andmete paljundamine, taastekitamine, kopeerimine, salvestamine elektroonsesse süsteemi või edastamine ükskõik millises vormis või millisel teel ilma Eesti Standardimis- ja Akrediteerimiskeskuse kirjaliku loata on keelatud.

Kui Teil on küsimusi standardite autoriõiguse kaitse kohta, võtke palun ühendust Eesti Standardimis- ja Akrediteerimiskeskusega: Koduleht www.evs.ee; telefon 605 5050; e-post info@evs.ee

The right to reproduce and distribute standards belongs to the Estonian Centre for Standardisation and Accreditation

No part of this publication may be reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, without a written permission from the Estonian Centre for Standardisation and Accreditation.

If you have any questions about standards copyright protection, please contact the Estonian Centre for Standardisation and Accreditation: Homepage www.evs.ee; phone +372 605 5050; e-mail info@evs.ee

EUROPEAN STANDARD

EN ISO 15798

NORME EUROPÉENNE

EUROPÄISCHE NORM

February 2022

ICS 11.040.70

Supersedes EN ISO 15798:2013, EN ISO
15798:2013/A1:2017

English Version

Ophthalmic implants - Ophthalmic viscosurgical devices (ISO 15798:2022)

Implants ophtalmiques - Dispositifs ophtalmiques
viscoélastiques (ISO 15798:2022)

Ophthalmische Implantate - Viskoelastische
Substanzen (ISO 15798:2022)

This European Standard was approved by CEN on 17 January 2022.

CEN members are bound to comply with the CEN/CENELEC Internal Regulations which stipulate the conditions for giving this European Standard the status of a national standard without any alteration. Up-to-date lists and bibliographical references concerning such national standards may be obtained on application to the CEN-CENELEC Management Centre or to any CEN member.

This European Standard exists in three official versions (English, French, German). A version in any other language made by translation under the responsibility of a CEN member into its own language and notified to the CEN-CENELEC Management Centre has the same status as the official versions.

CEN members are the national standards bodies of Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Norway, Poland, Portugal, Republic of North Macedonia, Romania, Serbia, Slovakia, Slovenia, Spain, Sweden, Switzerland, Turkey and United Kingdom.



EUROPEAN COMMITTEE FOR STANDARDIZATION
COMITÉ EUROPÉEN DE NORMALISATION
EUROPÄISCHES KOMITEE FÜR NORMUNG

CEN-CENELEC Management Centre: Rue de la Science 23, B-1040 Brussels

European foreword

This document (EN ISO 15798:2022) has been prepared by Technical Committee ISO/TC 172 "Optics and photonics" in collaboration with Technical Committee CEN/TC 170 "Ophthalmic optics" the secretariat of which is held by DIN.

This European Standard shall be given the status of a national standard, either by publication of an identical text or by endorsement, at the latest by August 2022, and conflicting national standards shall be withdrawn at the latest by August 2022.

Attention is drawn to the possibility that some of the elements of this document may be the subject of patent rights. CEN shall not be held responsible for identifying any or all such patent rights.

This document supersedes EN ISO 15798:2013.

Any feedback and questions on this document should be directed to the users' national standards body/national committee. A complete listing of these bodies can be found on the CEN website.

According to the CEN-CENELEC Internal Regulations, the national standards organizations of the following countries are bound to implement this European Standard: Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Norway, Poland, Portugal, Republic of North Macedonia, Romania, Serbia, Slovakia, Slovenia, Spain, Sweden, Switzerland, Turkey and the United Kingdom.

Endorsement notice

The text of ISO 15798:2022 has been approved by CEN as EN ISO 15798:2022 without any modification.

Contents

Page

Foreword.....	iv
1 Scope.....	1
2 Normative references.....	1
3 Terms and definitions.....	2
4 Intended performance.....	3
5 Design attributes.....	4
5.1 General.....	4
5.2 Characterization of the components.....	4
5.3 Characterization of the finished product.....	4
5.3.1 General.....	4
5.3.2 Absolute complex viscosity.....	5
5.3.3 Chemical and biological contaminants.....	5
5.3.4 Concentration.....	5
5.3.5 Elasticity.....	5
5.3.6 Molecular mass distribution.....	5
5.3.7 Osmolality.....	5
5.3.8 Particulates.....	6
5.3.9 pH.....	6
5.3.10 Refractive index.....	6
5.3.11 Shear viscosity.....	6
5.3.12 Spectral transmittance.....	6
5.4 Usability.....	7
6 Design evaluation.....	7
6.1 General.....	7
6.2 Evaluation of biological safety.....	7
6.2.1 General.....	7
6.2.2 Bacterial endotoxins test.....	8
6.2.3 Clearance of residual OVD from the anterior chamber.....	8
6.2.4 Degradation and toxicokinetics.....	8
6.2.5 Evaluation of inflammation and intraocular pressure.....	8
6.3 Clinical evaluation.....	8
6.3.1 General.....	8
6.3.2 Clinical investigation design.....	9
6.3.3 Corneal endothelial cell density.....	9
6.3.4 Postoperative inflammation.....	9
6.3.5 Post-operative intraocular pressure change.....	10
6.3.6 Adverse events.....	10
7 Sterilization.....	10
8 Product stability.....	11
9 Integrity and performance of the delivery system.....	11
10 Packaging.....	11
10.1 Protection from damage during storage and transport.....	11
10.2 Maintenance of sterility in transit.....	11
11 Information to be supplied by the manufacturer.....	11
Annex A (normative) Intraocular implantation test.....	13
Annex B (informative) Patient numbers for clinical investigation of intraocular pressure.....	16
Annex C (informative) Analyses of OVD clinical data.....	17
Bibliography.....	19

Foreword

ISO (the International Organization for Standardization) is a worldwide federation of national standards bodies (ISO member bodies). The work of preparing International Standards is normally carried out through ISO technical committees. Each member body interested in a subject for which a technical committee has been established has the right to be represented on that committee. International organizations, governmental and non-governmental, in liaison with ISO, also take part in the work. ISO collaborates closely with the International Electrotechnical Commission (IEC) on all matters of electrotechnical standardization.

The procedures used to develop this document and those intended for its further maintenance are described in the ISO/IEC Directives, Part 1. In particular, the different approval criteria needed for the different types of ISO documents should be noted. This document was drafted in accordance with the editorial rules of the ISO/IEC Directives, Part 2 (see www.iso.org/directives).

Attention is drawn to the possibility that some of the elements of this document may be the subject of patent rights. ISO shall not be held responsible for identifying any or all such patent rights. Details of any patent rights identified during the development of the document will be in the Introduction and/or on the ISO list of patent declarations received (see www.iso.org/patents).

Any trade name used in this document is information given for the convenience of users and does not constitute an endorsement.

For an explanation of the voluntary nature of standards, the meaning of ISO specific terms and expressions related to conformity assessment, as well as information about ISO's adherence to the World Trade Organization (WTO) principles in the Technical Barriers to Trade (TBT) see www.iso.org/iso/foreword.html.

This document was prepared by Technical Committee ISO/TC 172, *Optics and photonics*, Subcommittee SC 7, *Ophthalmic optics and instruments*, in collaboration with the European Committee for Standardization (CEN) Technical Committee CEN/TC 170, *Ophthalmic optics*, in accordance with the Agreement on technical cooperation between ISO and CEN (Vienna Agreement).

This fourth edition cancels and replaces the third edition (ISO 15798:2013 and its Amendment, ISO 15798:2013/Amd.1:2017), which has been technically revised.

The main changes compared to the previous edition are as follows:

- a) Inclusion of applicable sections from ISO 14630 throughout the document, but removal of any reference to that standard. It was further clarified that ophthalmic viscosurgical devices (OVD) are no implant by their intended use but are likely to share some of the risks related to non-active implants. Therefore, the following clauses and subclauses have been revised: [Clauses 4](#) and [5](#), [6.1](#), [6.2.1](#), [Clause 7](#). A new subclause [5.4](#) has been added.
- b) minor clarifications in [Clause 3](#) ([3.3](#), [3.4](#)) and addition of term *surgical invasive medical device*;
- c) clarification in [Clause 4](#) that a recommended removal procedure shall enable removal of the OVD as completely as possible;
- d) revised wording in [5.2](#) to align with defined terminology from [Clause 3](#);
- e) revised note in [5.3.2](#): narrowed recommended measuring range;
- f) revised note in [5.3.8](#): more accurate description of the risk;
- g) clarification that control OVD for the intraocular implantation test and the clinical investigation shall be the same in both studies; therefore, the following subclauses have been revised: [6.1](#), [6.2.5](#), [6.3.2](#), and [Annex A](#);
- h) revised wording in [6.2.2](#) of this document to include ISO 15798:2013/Amd.1:2017 and guidance on standard LAL-test;

- i) revised wording in [6.2.3](#) to address the potential risk of interaction of the OVD with fluorescence or radioisotope labelling;
- j) revised [6.3](#) to clarify requirement of a clinical evaluation, clarification of the clinical investigation protocol, revision of the clinical investigation design, and additional standardization for evaluation and reporting of result from the clinical investigation;
- k) inclusion of reference to ISO 10993-7 for acceptable levels of ethylene oxide and ethylene chlorohydrin in [Clause 7](#);
- l) packaging integrity has been specifically included into the scope of product stability [Clause 8](#); in addition, reference to ISO 14971 has been included into this clause;
- m) “Do not use if sterile barrier is breached” has been aligned with the recommended wording from ISO 15223-1 “Do not use if package is damaged”; in addition, molecular mass distribution has been removed from the list of information to be supplied by the manufacturer in [Table 1](#);
- n) major revision of [Annex A](#);
- o) correction of a typo in the formula for calculating the minimum number of evaluable patients per treatment group in [Annex B](#).
- p) Addition of new informative [Annex C](#) on analyses of OVD clinical data.

Any feedback or questions on this document should be directed to the user’s national standards body. A complete listing of these bodies can be found at www.iso.org/members.html.

Ophthalmic implants — Ophthalmic viscosurgical devices

1 Scope

This document is applicable to ophthalmic viscosurgical devices (OVDs), a class of surgical invasive medical devices with viscous and/or viscoelastic properties, intended for use during surgery in the anterior segment of the human eye. OVDs are designed to create and maintain space, to protect intraocular tissues and to manipulate tissues during surgery.

This document specifies requirements with regard to safety for the intended performance, design attributes, preclinical and clinical evaluation, sterilization, product packaging, product labelling and information supplied by the manufacturer of these devices.

2 Normative references

The following documents are referred to in the text in such a way that some or all of their content constitutes requirements of this document. For dated references, only the edition cited applies. For undated references, the latest edition of the referenced document (including any amendments) applies.

ISO 10993-1, *Biological evaluation of medical devices — Part 1: Evaluation and testing within a risk management process*

ISO 10993-6, *Biological evaluation of medical devices — Part 6: Tests for local effects after implantation*

ISO 10993-7, *Biological evaluation of medical devices — Part 7: Ethylene oxide sterilization residuals*

ISO 10993-9, *Biological evaluation of medical devices — Part 9: Framework for identification and quantification of potential degradation products*

ISO 10993-16, *Biological evaluation of medical devices — Part 16: Toxicokinetic study design for degradation products and leachables*

ISO 11135, *Sterilization of health-care products — Ethylene oxide — Requirements for the development, validation and routine control of a sterilization process for medical devices*

ISO 11137-1, *Sterilization of health care products — Radiation — Part 1: Requirements for development, validation and routine control of a sterilization process for medical devices*

ISO 11137-2, *Sterilization of health care products — Radiation — Part 2: Establishing the sterilization dose*

ISO 11137-3, *Sterilization of health care products — Radiation — Part 3: Guidance on dosimetric aspects of development, validation and routine control*

ISO 11607-1, *Packaging for terminally sterilized medical devices — Part 1: Requirements for materials, sterile barrier systems and packaging systems*

ISO 13408-1, *Aseptic processing of health care products — Part 1: General requirements*

ISO 14155, *Clinical investigation of medical devices for human subjects — Good clinical practice*

ISO 14971, *Medical devices — Application of risk management to medical devices*

ISO 17665-1, *Sterilization of health care products — Moist heat — Part 1: Requirements for the development, validation and routine control of a sterilization process for medical devices*

ISO 22442-1, *Medical devices utilizing animal tissues and their derivatives — Part 1: Application of risk management*

ISO 22442-2, *Medical devices utilizing animal tissues and their derivatives — Part 2: Controls on sourcing, collection and handling*

ISO 22442-3, *Medical devices utilizing animal tissues and their derivatives — Part 3: Validation of the elimination and/or inactivation of viruses and transmissible spongiform encephalopathy (TSE) agents*

EN 1041, *Information supplied by the manufacturer of medical devices*

3 Terms and definitions

For the purposes of this document, the following terms and definitions apply.

ISO and IEC maintain terminological databases for use in standardization at the following addresses:

- ISO Online browsing platform: available at <https://www.iso.org/obp>
- IEC Electropedia: available at <http://www.electropedia.org/>

3.1

absolute complex viscosity

$$|\eta^*| = [(\eta')^2 + (\eta'')^2]^{0,5}$$

absolute value of *complex viscosity* (3.2)

Note 1 to entry: Absolute complex viscosity is expressed in pascal seconds (Pa·s).

3.2

complex viscosity

$$\eta^* = \eta' - i \cdot \eta''$$

viscosity consisting of a viscous η' and an elastic η'' component where i is an imaginary number defined by $i = (-1)^{0,5}$

3.3

delivery system

primary container in which the product is supplied and any additional components provided to introduce the product into the eye

3.4

elasticity

$$G' = \sigma_0 / \varepsilon_0 \cdot \cos \delta$$

tendency of a body to return to its original shape after having been deformed

Note 1 to entry: Elasticity is quantitatively defined as stress (the force generated within the body) divided by strain (the change in dimensions of the body) multiplied by cosine of the phase lag between stress and strain.

Note 2 to entry: Elasticity is expressed in pascal (Pa).

3.5

lost to follow-up subject

subject for which the final post-operative case report form is overdue and who cannot be contacted despite extensive written and telephone follow-ups to determine the final clinical outcome

Note 1 to entry: This category does not include subjects who have died.

3.6

ophthalmic viscosurgical device

OVD

generic term that includes a variety of materials with viscous and/or viscoelastic properties, which are designed to create and maintain space, to protect intraocular tissues and to manipulate tissues during surgery in the anterior segment of the human eye